Pediatric sepsis: Important considerations for diagnosing and managing severe infections in infants, children, and adolescents

Citation
Randolph, Adrienne G., and Russell J McCulloh. 2014. “Pediatric sepsis: Important considerations for diagnosing and managing severe infections in infants, children, and adolescents.” Virulence 5 (1): 179-189. doi:10.4161/viru.27045. http://dx.doi.org/10.4161/viru.27045.

Published Version
doi:10.4161/viru.27045

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064516

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Pediatric sepsis
Important considerations for diagnosing and managing severe infections in infants, children, and adolescents

Adrienne G Randolph1,2,* and Russell J McCulloh3

1Harvard Medical School; Boston, MA USA; 2Department of Anesthesia, Perioperative and Pain Medicine; Boston Children’s Hospital; Boston, MA USA; 3Children’s Mercy Hospital; Kansas City, MO USA

Keywords: infants, children, pediatric, sepsis, septic shock, infection, innate immunity, review

Sepsis is the leading cause of death in children worldwide. Although the diagnosis and management of sepsis in infants and children is largely influenced by studies done in adults, there are important considerations relevant for pediatrics. This article highlights pediatric-specific issues related to the definition of sepsis and its epidemiology and management. We review how the capacity of the immune system to respond to infection develops over early life. We also bring attention to primary immune deficiencies that should be considered in children recurrently infected with specific types of organisms. The management of pediatric sepsis must be tailored to the child’s age and immune capacity, and to the site, severity, and source of the infection. It is important for clinicians to be aware of infection-related syndromes that primarily affect children. Although children in developed countries are more likely to survive severe infections than adults, many survivors have chronic health impairments.

Introduction

Sepsis is the most common cause of death in infants and children worldwide. Childhood pneumonia has an estimated incidence of 0.29 episodes per child-year in pre-developed and 0.05 episodes per child-year in developed countries, making it the most common cause of pediatric sepsis; it is also the leading cause of mortality in children less than 5 y of age. Pre-developed countries with large populations of children bear the major burden of pediatric sepsis. Of the approximately 156 million new cases of pneumonia per year worldwide, 151 million are estimated to be in the developing world where a combination of contaminated water, poor sanitation, indoor air pollution, crowding, low birth weight, and insufficient immunization and nutrition allow pathogens to invade and multiply relatively unchecked in the body. This is why the first tier of the three tiered approach to the prevention of pediatric sepsis and its sequelae outlined in Figure 1 requires escalation of public health initiatives to remedy these issues. The second tier includes early identification and intervention to prevent sepsis progression from infection to sepsis to septic shock with end-organ damage. The third prevention tier includes intensive care supportive interventions to prevent sepsis-related death and disability.

In this review, we limit our discussion to sepsis in term infants that have been exposed to the home environment through adolescents under 18 y of age. We exclude much of the discussion of perinatal and neonatal sepsis which is covered elsewhere in this special issue. The purpose of this article is to highlight the major differences between adults and children in the diagnosis of sepsis, the response of the immune system to infection, and the management of infants, children, and adolescents with life-threatening infections.

Pediatric Definitions of Sepsis, Severe Sepsis, and Septic Shock

When pediatricians use the term “sepsis”, they usually are referring to an infection that overwhelms the host causing capillary leak, hypotension, and/or respiratory failure. Relatively stable children admitted to the hospital with complicated pneumonia, pyelonephritis, invasive cellulitis, or bronchilitis are given these descriptive discharge diagnoses even though most could be given the diagnosis of “sepsis” according to the definitions published in 2005 from the International Consensus Conference on Pediatric Sepsis (see Table 1). Those sepsis definitions were created to facilitate enrollment of children into clinical trials of anti-sepsis agents. They were modified only slightly from the consensus sepsis definitions created for adult patients originally published in 1992.

Briefly, to be septic, a child must have a confirmed or suspected infection and signs of a systemic response to that infection. Severe sepsis requires diagnosis of end organ system involvement. Septic shock requires cardiovascular dysfunction that is not resolved by initial fluid resuscitation. These definitions were aimed at identifying sepsis in an early stage to facilitate early intervention, with the goal of stopping further spread of infection and preventing a severe life-threatening inflammatory reaction to infection.

One major difference in the definition of sepsis in children vs. adults are the age-specific cutoffs for physiologic and organ...
system-related laboratory parameters. The healthy pediatric cardiovascular system can maintain cardiac output by employing extreme tachycardia for a prolonged period without inducing myocardial ischemia. Compared with adults, hypotension presents later in children and often portends imminent and potentially non-reversible cardiovascular collapse. As a result, the pediatric consensus guidelines are designed to identify patients with compensated septic shock in the hope that early intervention will prevent cases of profound decompensation leading ultimately to death. Consequently, children whose physical exam reveals cold extremities with delayed capillary refill despite receipt of boluses of intravenous fluid are diagnosed with septic shock and are treated similarly to children with life-threatening vasopressor-dependent decompensated septic shock. Although rigorous studies on the impact of these broadly encompassing sepsis definitions on clinical outcomes are lacking, there are some data to support that early recognition and treatment of sepsis can be life-saving for children in developed and pre-developed countries.

Response to Infection by the Developing Immune System

A child’s immune system is remarkably different from adults in terms of innate and adaptive immune function; in fact, full immunologic maturity is not reached until adolescence. The transition from a sterile, intrauterine environment, to the ecologically complex and changing microbiologic milieu that the infant must confront for the remainder of his or her lifetime, requires extreme shifts in immune function. Neonates are the most profoundly immune compromised, and their immune system is typified by comparatively poor innate and adaptive immune responses. In part, this gives them a survival advantage because a relatively suppressed immune system allows the newborn to tolerate colonization of previously sterile skin and gastrointestinal tract with normal bacterial flora without triggering an overwhelming inflammatory response. In neonates, phagocytes are less responsive to pathogen-associated molecular patterns (PAMPs) than adult cells, have diminished adhesion and extravasation activity, produce fewer pro-inflammatory cytokines, and have diminished antigen presentation activity to adaptive immune cells. Natural killer (NK) cells are less cytotoxic as well and complement levels are also only 10–70% of adult levels.

Adaptive immunity is also suppressed in the very young. Although T cell levels are much higher in neonates than adults, their functionality is relatively poor, due in part to low production of interleukin-2 (IL-2). Helper CD4⁺ T cells are skewed toward Th-2 (humoral) responses in the neonate due to low production of interferon-γ (IFNγ), and cytotoxic CD8⁺ T cells are less active. B cells, although also abundant in the neonate, are predominantly naïve, produce mostly IgM immunoglobulins (Igs), and are poorly responsive to capsular polysaccharides. By 2 y of age, adaptive and immune responses have largely approached those of healthy adult levels, but full immune competence is not truly reached until the teenage years.

The cumulative result of these deficits in immune function is that infants and some toddlers have markedly increased susceptibility to severe infection from various organisms, particularly viruses and encapsulated bacteria. Susceptibility to severe viral infection is most prominent in children less than 2 y old due in part to unchecked viral replication caused by lower production of IFNγ and diminished cytotoxic lymphocyte responses. The

**Figure 1.** Depiction of primary, secondary, and tertiary pediatric sepsis prevention efforts (modified, with permission from Dr Bala Totapally).
primary mitigating factor during the first 6 mo of life is transplacentally acquired maternal antibody (primarily IgG and IgA), a reason for expanding the recommendations for maternal immunization to include coverage of common pathogens associated with severe pediatric illness.23 Additionally, the use of protein-polysaccharide conjugate vaccines can stimulate infant immune systems to produce protective levels of immunoglobulin to polysaccharide-encapsulated pathogens, including *Haemophilus influenzae* type b (*Hib*) and *Streptococcus pneumoniae* (*S. pneumoniae*).24,25 Such vaccines can even change nasopharyngeal carriage of pathogens, conferring a benefit to the community.26 Unfortunately, vaccines to common viral pathogens, particularly influenza, are not approved for children less than 6 mo old and are poorly immunogenic in children <2 y old compared with older children and adults.27

**Epidemiology and Clinical Manifestations of Pediatric Sepsis**

The estimated overall prevalence of severe sepsis among children living in the United States increased steadily from 0.56 cases per 1000 children in 1995 to 0.63 cases per 1000 children in 2000, to 0.89 cases per 1000 children in 2005, with most of this increase due to newborn sepsis.3,28,29 For example, estimated prevalence of sepsis in US newborns is 9.7/1000 population, non-newborn infants 2.25/1000, and the rates are 0.23 to 0.52/1000 in subgroups of children 1–19 y of age.29 Such variation at the early extremes of life mirrors the markedly high rates reported in advanced elderly patients compared with younger adults.30 In fact, the clinical presentation of sepsis in 18- to 30-y-olds is very similar to the profile encountered in 12- to 17-y-olds and very different from patients aged 65 y and over. Also similar to adults, common pathogens causing sepsis in children differ not only by local geography but by age and medical co-morbidities.

In neonates presenting with late-onset sepsis, the most common bacterial pathogens include group B streptococci (GBS) and enteric gram-negative rods, especially *Escherichia coli*.31 Peripartum prophylaxis protocols have reduced the incidence of GBS-related sepsis.32 *Bordatella pertussis* can cause a severe illness in young infants, characterized by recurrent episodes of gagging, apnea, cyanosis, and bradycardia and with high mortality in those that develop respiratory failure and pulmonary hypertension.33-36

| Clinical syndrome                  | Criteria                                                                                      |
|-----------------------------------|---------------------------------------------------------------------------------------------|
| Systemic inflammatory response syndrome (SIRS) | Must have at least 2 of the following of which at least one must be abnormal temperature or abnormal leukocyte count: |
|                                   | 1. Abnormal heart rate (HR) defined as tachycardia (HR >2 SD above normal for age in the absence of external stimulus, drugs, or painful stimuli; or otherwise unexplained elevation over 0.5–4 h) or bradycardia (HR <10th percentile for age in absence of external vagal stimulus, drugs, congenital heart disease; or otherwise unexplained HR depression >0.5 h). |
|                                   | 2. Tachypnea >2 SD above normal for age or mechanical ventilation for process other than anesthesia or underlying neuromuscular disease |
|                                   | 3. Abnormal temperature defined as fever (core temperature >38.5 °C) or hypothermia (core temperature <36 °C). |
|                                   | 4. Abnormal leukocyte profile with counts either elevated or depressed for age (not due to chemotherapy); or >10% immature neutrophils |
| Infection                         | A suspected infection or one proven by positive culture, tissue stain, or molecular testing caused by any pathogen or a clinical syndrome associated with a high probability of infection. Acceptable evidence can include physical exam, laboratory, or radiologic findings |
| Sepsis                            | SIRS resulting from or occurring in the presence of proven infection                           |
| Severe sepsis                     | Sepsis plus the following: cardiovascular organ dysfunction, acute respiratory distress syndrome (ARDS), or two or more other organ dysfunctions |
| Septic shock                      | Sepsis (defined above) and the following signs of cardiovascular organ dysfunction that remain after initial fluid resuscitation (40 ml/kg intravascularly in ≤1 h): |
|                                   | • Decrease in BP (hypotension) <5th percentile for age or systolic BP >2 SD below normal for age; OR |
|                                   | • Need for vasoactive drug to maintain BP in normal range (dopamine >5 µg/kg/min or epinephrine, or norepinephrine at any dose); OR |
|                                   | • At least two of the following |
|                                   | - Unexplained metabolic acidosis: base deficit >5.0 mEq/L; |
|                                   | - Increased arterial lactate >2 times upper limit of normal |
|                                   | - Oliguria: urine output <0.5 mL/kg/h |
|                                   | - Prolonged capillary refill: >5 s |
|                                   | - Core to peripheral temperature gap >3 °C |

Adapted from reference 6.
of the highest rate of hospitalizations and the highest number of deaths. Thus, although vaccination may prevent the majority of influenza-related severe respiratory infections, low vaccination rates, decreased vaccine response in young children, and periods of poor match between circulating viruses and influenza vaccine lead to an ongoing healthcare burden. Although parainfluenza virus most commonly stays in the upper airway causing croup mostly in healthy children, it can cause severe pneumonia in the very young and in children with compromised immune or respiratory symptoms as can adenovirus.

Bronchiolitis, a viral lower respiratory tract infection syndrome characterized by hyperinflation, increased mucous production, air trapping, and wheezing, affects 1–2% of infants worldwide. Although respiratory syncytial virus (RSV) is identified in the majority of infants hospitalized for bronchiolitis in the developed world, very few of these infants die if given supportive care. Human metapneumovirus and rhinovirus are increasingly identified as a cause of hospitalization for bronchiolitis in infants. Risk factors for life-threatening bronchiolitis and viral sepsis include prematurity, chronic lung disease, congenital cardiac abnormalities, and primary immunodeficiency.

Viral–bacterial co-infection occurs in up to 23% of cases of severe pneumonia, resulting in a higher likelihood of respiratory failure and septic shock. The viral infection is thought to precede and predispose children to bacterial invasion. For example, MRSA was recently reported to be associated with mortality in previously healthy children infected with influenza, especially in the 2009 influenza pandemic where this fatal coinfection was a strong mortality predictor causing unrelenting destruction of lung despite appropriate antibiotics. Although the mechanism underlying viral–bacterial coinfection is unclear, this highest risk subgroup of children with influenza–S. aureus co-infection were shown in one study to be more likely than those with influenza alone to have cytokine storm that coexisted with a decreased monocyte response to ex vivo stimulation with lipopolysaccharide (aka “immunoparalysis”). Neonates are susceptible to overwhelming viral sepsis from herpetic simplex virus (HSV), enterovirus, and parechoviruses, and profoundly immune-compromised children from cancer or HIV can develop sepsis from HSV, acute cytomegalovirus, adeno-virus, or Epstein–Barr virus infections. Aside from influenza virus, older children and adolescents with healthy immune and cardiorespiratory systems are rarely hospitalized for viral sepsis.

Diarrheal diseases are another major cause of sepsis in infants and children, especially in the pre-developed world. Public health sanitation interventions and availability of clean water are essential and highly effective in decreasing sepsis-related mortality in children worldwide. In developed countries, rotavirus can lead to a profound diarrhea and sepsis-like picture in very young children prompting development of the rotavirus vaccine.

Several other pathogens cause sepsis primarily in pre-developed countries. Dengue virus, a mosquito-borne flavivirus endemic to many tropical countries, causes a sepsis syndrome typified by capillary leak and disseminated intravascular coagulation (DIC). Malaria—particularly *Plasmodium falciparum*—can cause sepsis in young children and HIV-infected children;
Sepsis is often seen in association with cerebral malaria presenting with symptoms of altered mental status, convulsions, and acidosis. Burkholderia pseudomallei, or melioidosis, seen in southeast Asia, can present with pulmonary symptoms and fever.

Less common causes of sepsis should be considered as well, depending on risk factors. Fungal pathogens, particularly Candida species, cause up to 10% of severe septic shock in children. Depending on geographic exposures, tick-borne diseases that can present as encephalitis meeting criteria for sepsis include Rocky Mountain Spotted Fever and ehrlichiosis. Salmonella species should be considered, particularly in children with functional asplenia and those who are malnourished. In endemic areas, children with immune compromise and/or asplenia are at risk for babesiosis. Finally, it is important to note that, despite advances in microbiologic detection methods, the underlying cause of sepsis remains unknown in up to 75% of pediatric cases.

**Primary and Acquired Immune Deficiency in Sepsis**

Although neonates, infants, and young children are at increased risk for severe infection and sepsis compared with older children and adolescents, it is critical to recognize recurring patterns of infection or severe clinical presentations suggesting that the child may have an underlying immune deficiency. A thorough evaluation for a primary immune deficiency should include a detailed medical history that includes gestation, birth, growth, development, and immunizations, a family history, and a history of prior infections with special attention to pathogens identified and sites of infection. Screening labs can then be considered in conjunction with specialist consultation. Table 2 lists pathogens and clinical presentations associated with selected primary immune deficiency categories.

Human immunodeficiency virus increases the risk for sepsis in infected children substantially, although this risk is mitigated with antiretroviral therapy use. Similar to severe combined immune deficiency syndromes (SCID) and other disorders of T-cell function, sepsis can arise from infection with typical pathogens (e.g., S. pneumoniae), from invasive fungal infections or from opportunistic infection such as disseminated mycobacterial infection. In pre-developed countries, HIV infection is significantly associated with disseminated infection from Mycobacterium tuberculosis as well.

**Management of Sepsis in Infants and Children Compared with Adults**

In part, due to the challenge of performing clinical trials in children with sepsis-related critical illness there are a paucity of strong data from rigorous and appropriately-powered clinical trials to guide the management of children with severe sepsis. Consequently, published recommendations for sepsis management in infants and children closely mimic those for adult patients. The Surviving Sepsis Guidelines (2012 update) lists few differences in pediatric management recommendations from those in adults and these are summarized in Table 3. Of primary importance, as in adult patients with sepsis, is to provide empiric antimicrobial therapy that treats potential causative pathogens based on a patient’s age and exposure history. Full discussion of the details of managing sepsis in children is beyond the scope of this article, but we do note a few unique aspects of treating the pediatric septic patient. One major difference in how children with refractory septic shock and/or refractory hypoxemia from severe respiratory tract infection are clinically managed compared with adults is a higher use of extracorporeal life support (ECLS) as rescue therapy. ECLS survival rates in children with severe pneumonia and refractory septic shock reported by the ELSO registry are 50% and are above 80% in those who have single organ failure (refractory respiratory failure) triggered viral infection.

Additionally, early use of goal-directed therapeutic targets, such as rapid and repeated fluid resuscitation, and early institution of vasopressor support when fluid resuscitation fails, are associated with decreased mortality in meningococcemia. This aggressive fluid resuscitation strategy has been extrapolated to pediatric treatment recommendations for other causes and presentations of pediatric sepsis. Recent data from the FEAST trial of fluid management in over 3000 African children showed markedly higher mortality those with compensated shock randomized to receive repeated boluses of saline or alburnin compared with children who did not receive fluid boluses. Although these children had high rates of malaria and severe anemia, secondary analyses did not identify them as contributors to the increased mortality in the children receiving fluids. The results of the FEAST trial have raised concerns internationally as to whether the aggressive use of fluid boluses even in developed countries might harm children with compensated shock. Positive fluid balance has been associated with worse clinical outcome in other studies of critically ill children, many of whom had sepsis. Table 4 lists multiple pediatric sepsis resources that provide additional recommendations regarding management.

**Factors Influencing Pediatric Sepsis-Related Mortality**

Although children <12 mo old have the highest risk of death from sepsis, much of this mortality is driven by the high incidence of sepsis and the high rate of sepsis-related mortality in infants born very prematurely. Compared with older children, infants have the highest incidence of severe sepsis but much of it is viral and most will survive hospitalization. A higher mortality among male patients, suggested by studies in adult patients and animals, appears less prominent in children, although males are more likely to be hospitalized in infancy for severe infections. The incidence of malignancies and other chronic respiratory and cardiac conditions in children rises with age and contributes to sepsis-related mortality; the majority of older children hospitalized with sepsis have underlying conditions impairing their immune or cardiorespiratory systems.

Site of infection also is related to likelihood of severe sepsis and death, with endocarditis and CNS infections associated with the
highest mortality rates (21.1% endocarditis, 17.1% CNS infections). Certain organisms are associated with worse prognosis, particularly fungi, and infections with antibiotic-resistant bacteria, including MRSA, gram-negative bacilli, and nosocomial pathogens. The extent of systemic involvement is also very important, as children who develop multiple organ system failure from sepsis have the lowest likelihood of surviving. Survival from sepsis, after adjusting for sepsis severity, is usually higher in children compared with adults. In a large pediatric clinical trial of recombinant human-activated Protein C in pediatric septic shock, mortality in the cohort of the septic children enrolled (who were all mechanically ventilated and on vasopressors) was approximately 17% compared with rates of 26–34% in clinical trials in adult sepsis and septic shock patients who did not have to be mechanically ventilated to gain entry.

Although there are a paucity of national-level data on pediatric sepsis outcomes from pre-developed countries, the World Federation of Pediatric Intensive and Critical Care Societies (WFPIICS) is working to change this through their global sepsis initiative (http://www.wfpiccs.org). Sepsis mortality has been reported in studies of dengue fever and specific infections but few trials in pre-developed countries have enrolled a heterogeneous group of children with sepsis. Over half of African children in the multicenter FEAST trial that presented with hypotension and decompensated shock died. In the group that included mostly children with compensated septic shock,

| Underlying type of immune deficiency | Example/etiology | Associated infections and infection-related syndromes |
|-------------------------------------|-----------------|-----------------------------------------------------|
| Agammaglobulinemias                 |                 |                                                     |
| All Ig isotypes deficient or absent | X-linked agammaglobulinemia | Hib, S. pneumoniae (recurrent respiratory infections) |
|                                    |                 | Giardia lamblia, rotavirus (chronic diarrhea)        |
|                                    |                 | Enterovirus (chronic meningoencephalitis)            |
| One or more (but not all) Ig isotypes reduced/absent | Common variable immune deficiency (CVID) | Hib, S. pneumoniae (recurrent respiratory infections) |
|                                    |                 | C. jejuni, Salmonella spp., Giardia (gastrointestinal infections) |
|                                    |                 | Autoimmune disease                                   |
|                                    |                 | Recurrent/severe sinuspulmonary infections           |
|                                    |                 | P. jirovecii infection in first year of life         |
|                                    |                 | Cryptosporidium, Giardia                             |
|                                    |                 | Autoimmune disorders                                 |
| Immunoglobulin class switch recombination disorders | Hyper-IgM syndromes | Sepsis, disseminated infection from meningococci, N. gonorrhoeae |
| Common pathway                     | C3              | Bacteremia or sepsis from H. influenzae, S. pneumoniae, meningococci, encapsulated bacteria |
| Mannose-binding lectin (MBL) pathway | Polymorphisms with low MBL levels | Meningococci, S. pneumoniae, among others |
| Late complement defects and alternative pathway defects | C5–C9, properdin | Recurrent respiratory, skin, and soft tissue infections with S. aureus, oculocutaneous albinism |
| Phagocyte disorders                |                 |                                                     |
| Absent/defective oxidative burst   | Chronic granulomatous disease (CGD) | Burkholderia cepacia pneumonia, Nocardia spp., Aspergillus spp., S. aureus infections, liver abscesses |
| Decreased/absent hypochlorous acid production | Myeloperoxidase deficiency | Invasive Candida spp. infections |
| Lysosomal packaging disorder       | Chediak–Higashi syndrome | Recurrent respiratory, skin, and soft tissue infections with S. aureus, oculocutaneous albinism |
| Cell-mediated immunity             |                 |                                                     |
| T- and B-cell dysfunction          | Severe combined immunodeficiency syndrome (SCID) | Opportunistic infections (incl. P. jirovecii), fungal infections, invasive bacterial infections, persistent, severe viral infections (RSV, VZV, HSV, CMV), occurring in infancy |
| T-cell and NK cell disorders       | Ataxia–telangiectasia | Severe sinuspulmonary infections, ± opportunistic infections |
|                                    | Hyper Ig-E syndrome | Recurrent pneumonias from S. aureus, H. influenzae, S. pneumoniae, severe eczema |
|                                    | NK cell deficiency | Severe HSV, VZV, CMV infection beyond infancy |

Summarized from reference 114. Definitions: Ig, Immunoglobulin; Hib, H. influenzae type b; RSV, respiratory syncytial virus; VZV, varicella zoster virus; HSV, herpes simplex virus; CMV, cytomegalovirus; NK, natural killer.
mortality was 7.3–10.6% in the first 48 h after presentation and 8.7–12.2% at 4 weeks depending on the study arm. In addition, approximately 2% of survivors had severe neurologic sequelae.92

Summary

In this brief review, we have highlighted some of the major differences between the diagnosis, epidemiology, host immune response, treatment, and outcome of infants and children compared with adults. As shown in Figure 1, decreasing the high burden of sepsis in the pediatric population requires a multi-tiered approach. Prevention of sepsis is paramount and public health initiatives have been shown to be high-impact, cost-effective interventions. Early recognition of sepsis and initial management in the outpatient and hospital wards are essential for preventing progression to more severe forms. Supportive intensive care unit interventions such as mechanical ventilation, vasopressor infusions, and continuous monitoring modalities are essential for preventing sepsis-related disability and death.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Table 4. Selected resources and guidelines for clinicians related to pediatric sepsis

| Resource                                      | Location                                      | Comments                                                                                          |
|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------|
| Infectious Diseases Society of America        | http://www.idsociety.org                      | Provides links to clinical practice guidelines regarding the treatment of multiple bacteria and viruses for children including a guideline on management of pediatric community acquired pneumonia |
| Red Book                                      | aapredbook.aappublications.org                | In-depth pediatric infectious diseases resource published by the American Academy of Pediatrics     |
| World Health Organization Pocket book of hospital care for children: guidelines for the management of common illnesses with limited resources | http://www.who.int/child-adolescent-health/publications/CHILD_HEALTH/PB.htm | Provides diagnostic and treatment guidelines for managing children suffering from various illnesses, including severe infections and sepsis. |
| Centers for Disease Control Healthcare Infection Control Practices Advisory Committee (HICPAC) | http://www.cdc.gov/hicpac/pubs.html          | Publishes guidelines for prevention, surveillance, and treatment of nosocomial infections in multiple healthcare settings |
| UpToDate                                      | http://www.uptodate.com                      | Evidence-based clinician support at the point of care electronic resource with many chapters devoted to pediatric sepsis and pediatric infections. |
| American College of Critical Care Medicine Guidelines for the Management of Pediatric Septic Shock | Currently integrated into the American Heart Association Pediatric Advanced Life Support guidelines as well as from original source12 | Algorithm for the management of septic shock in children. |
| Surviving Sepsis Campaign Guidelines for the Management of Sepsis | http://www.survivingsepsis.org                | Evidence-based guidelines for the management of sepsis in adults and children.                     |

References

1. Bahl R, Martines J, Ali N, Bhan MK, Carlo W, Chan KY, Darmstadt GL, Hatem DH, Lawn JE, McMillan DD, et al. Research priorities to reduce global mortality from newborn infections by 2015. Pediatr Infect Dis J 2009; 28(Suppl):S43-8; PMID:19106763; dx.doi.org/10.1097/INF.0b013e31819585d7

2. Carcillo JA. Reducing the global burden of sepsis in infants and children: a clinical practice research agenda. Pediatr Crit Care Med 2005; 6(Suppl):S157-64; PMID:15857551; http://dx.doi.org/10.1097/01.PCC.0000161574.36857.CA

3. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epide- miology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701; PMID:12433670; http://dx.doi.org/10.1164/rccm.200207-682OC

4. Wiens MO, Kambakhsh E, Kisson N, Ansermino JM, Ndamira A, Larson CP. Pediatric sepsis in the developing world: challenges in defining sepsis and issues in post-discharge mortality. Clin Epideimiol 2012; 4:319-25; PMID:23226074; http://dx.doi.org/10.2147/CLEP.S335693

5. Rudan I, Boschi-Pinto C, Bieglov Z, Mulhallon K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86:408-16; PMID:18547544; http://dx.doi.org/10.2471/BLT.07.048769

6. Goldstein B, Girou B, Randolph; A. International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8; PMID:15366651; http://dx.doi.org/10.1097/01.PCC.000049131.72248.E6

7. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20:724-6; PMID:1597021; http://dx.doi.org/10.1097/00003348-199206000-00002

8. Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, Berg MD, de Caen AR, Fink EL, Freid EB, et al.; American Heart Association. Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1361-99; PMID:20956434; http://dx.doi.org/10.1542/peds.2010-2972D

9. Leterme S, Dhahane A, Salleron J, Grandbastien B, Lacoste J, Lederc F; Groupe Francophone de Réanimation et d’Urgences Pédiatriques (GFRUP). PELOD-2: an update of the PEDIatric organ dysfunction score. Crit Care Med 2013; 41:1761-73; PMID:23685639; http://dx.doi.org/10.1097/CCM.0b013e31828a2b24

10. Han YY, Carcillo JA, Dragotta MA, Bills DM, Watson RS, Westerman ME, Orr RA. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:789-93; PMID:14523168; http://dx.doi.org/10.1542/peds.112.4.793

11. Oliveira CF, Nogueira de Sá FR, Oliveira DS, Gottschald AF, Moura JD, Shihsa AR, Troster EJ, Vaz FA, Carcillo JA. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world. Pediatr Emerg Care 2008; 24:810-5; PMID:19096666; http://dx.doi.org/10.1097/PEC.0b013e3181e99f3a

12. Vyberg S, Nilsson A. The developing immune system - from foetus to toddler. Acta Paediatr 2012; 101:120-7; PMID:22058822; http://dx.doi.org/10.1111/j.1651-2227.2011.02494.x

13. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004; 173:4627-34; PMID:15383597

14. Levy O. Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol 2004; 76:999-25; PMID:15292276; http://dx.doi.org/10.1189/jlb.0504320

15. Levy O. Innate immunity of the human newborn: distinct cytokine responses to LPS and other Toll-like receptor agonists. J Endotoxin Res 2005; 11:113-6; PMID:15949138

16. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7:379-90; PMID:17457344; http://dx.doi.org/10.1038/nrz1207

17. Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009; 65:98R-105R; PMID:19918215; http://dx.doi.org/10.1203/01.PDR.0000318919f9d

18. Fleer A, Krediet TG. Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn. Neonatology 2007; 92:145-57; PMID:17467116; http://dx.doi.org/10.1155/2007/300082054

19. Maródi L. Innate cellular immune responses in newborns. Clin Immunol 2006; 118:137-44; PMID:16377252; http://dx.doi.org/10.1016/j.clim.2005.10.012

20. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. Am J Perinatol 2013; 30:105-12; PMID:23297181; http://dx.doi.org/10.1055/s-0033-1333412

21. Filias A, Theodorou GL, Moustopoulos S, Varvarigou AA, Mantagos S, Karakanta M. Phagocytic ability of neutrophils and monocytes in neonates. BMC Pediatr 2011; 11:29; PMID:21492472; http://dx.doi.org/10.1186/1471-2431-11-29

22. Saotou B, Filler G, Beguin Y. Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Exp Hematol 1997; 25:103-8; PMID:90152054

23. Healy CM, Baker CJ. Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis 2006; 19:271-6; PMID:16645489; http://dx.doi.org/10.1097/01.qco.0000226822.65595.5b
104. Leclerc F, Leteurtre S, Duhamel A, Grandbastien B, Proulx F, Martinot A, Gauvin F, Hubert P, Lacroix J. Cumulative influence of organ dysfunctions and septic state on mortality of critically ill children. Am J Respir Crit Care Med 2005; 171:348-53; PMID:15516535; http://dx.doi.org/10.1164/rccm.200405-630OC

105. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al.; REsearching severe Sepsis and Organ dysfunction in children: a global prospective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-43; PMID:1750452; http://dx.doi.org/doi.org/10.1016/S0140-6736(07)60411-5

106. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helderbrand JD, Ely EW, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709; PMID:11236773; http://dx.doi.org/10.1056/NEJM200103083441001

107. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdfeld B, Marshall JC, Rhodes A, Artigas A, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2002; 366:2059-64; PMID:2206830; http://dx.doi.org/10.1056/NEJMoa022290

108. Jawad I, Lukić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health 2012; 2:10404; PMID:23108133; http://dx.doi.org/10.7189/jogh.02.010404

109. Jaramillo-Bustamante JC, Martín-Agudelo A, Fernández-Laverde M, Baretto-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13:501-8; PMID:22460772; http://dx.doi.org/10.1097/PCC.0b013e318258e88f

110. Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, de Caen AR, Fink EL, Freid EB, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(Suppl 3):S876-908; PMID:20956230; http://dx.doi.org/10.1161/CIRCULATIONAHA.110.971101

111. Principles and Practice of Pediatric Infectious Diseases. 4th ed. Eds: Long SS, Pickering LK, Prober CG. Edinburgh: Elsevier, 2012; pp 600-41.